Excision BioTherapeutics Inc.
3624 Market St, Office# 514
Philadelphia
Pennsylvania
19104
United States
Website: http://www.excisionbio.com/
Email: info@excisionbio.com
38 articles with Excision BioTherapeutics Inc.
-
Excision BioTherapeutics to Host Key Opinion Leader Webinar on HIV and the Ongoing Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure
10/20/2022
Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases, today announced it will host a clinical expert webinar on HIV and the ongoing Phase 1/2 trial evaluating the Company’s CRISPR-based therapy EBT-101 as a potential cure for the disease.
-
Excision BioTherapeutics Awarded California Institute for Regenerative Medicine (CIRM) Grant to Support Ongoing Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV
9/29/2022
Excision BioTherapeutics, Inc. today announced that the California Institute for Regenerative Medicine (CIRM) has awarded Excision a $6.85 million grant to support the clinical development of the EBT-101 program for human immunodeficiency virus type 1 (HIV-1).
-
Excision BioTherapeutics Doses First Participant in EBT-101 Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV
9/15/2022
Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases, today announced that the first participant has been dosed in the Phase 1/2 clinical trial of EBT-101 for human immunodeficiency virus type 1 (HIV-1).
-
Excision BioTherapeutics to Present at Upcoming September 2022 Conferences
9/9/2022
Excision BioTherapeutics Inc. announced that Excision Management will present at the following upcoming investor conferences.
-
Excision BioTherapeutics to Participate in the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 2:00 p.m. ET
6/7/2022
Excision BioTherapeutics Inc., a biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases, today announced that company management is scheduled to present at the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 2:00 p.m. Eastern Time in New York City, NY.
-
Excision BioTherapeutics to Present Preclinical and Bioinformatic Data Showing Robust and Specific Editing of HIV Proviral DNA with EBT-101 at the ASGCT 25th Annual Meeting
5/17/2022
Excision BioTherapeutics Inc., a biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases, today announced that preclinical and bioinformatic data showing robust and specific editing of HIV proviral DNA with EBT-101 will be featured in an upcoming poster presentation at ASGCT.
-
Revealed in an article published in Science magazine, this new variant of HIV was discovered in individuals in the Netherlands, Belgium and Switzerland.
-
Clinical trial news definitely picked up this final week of January. Here’s a look.
-
Moderna invested heavily in mRNA technology to manufacture some 900 million doses of the COVID-19 vaccine. Now, the company has created an mRNA-based vaccine to prevent HIV.
-
Excision BioTherapeutics Initiates Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV
1/27/2022
Excision BioTherapeutics, Inc. today announced the initiation of a first-in-human (FIH) Phase 1/2 clinical trial of EBT-101 in individuals living with human immunodeficiency virus type 1 (HIV).
-
Exavir Therapeutics announced that it was able to eliminate HIV from human cells with lipid nanoparticle (LNP)-delivered Tat-targeted CRISPR-Cas9.
-
Excision BioTherapeutics Expands Management Team with Three Key Appointments
10/12/2021
Excision BioTherapeutics Inc., a biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases, today announced the expansion of its management team with the appointments of Sara Turken, J.D., as General Counsel, Manish Anand, M.Sc., as Senior Vice President, Regulatory Affairs, and Robert Gunning, CPA, CGMA, as VP, Controller.
-
The FDA's IND approval sets the stage for the very first Phase I/II trial to evaluate EBT-101 as a functional cure for chronic HIV based on the endpoints of safety, tolerability, and efficacy.
-
Excision Receives FDA Clearance of IND for Phase 1/2 Trial of EBT-101 CRISPR-Based Therapeutic for Treatment of HIV
9/15/2021
Excision BioTherapeutics, Inc., the developer of CRISPR-based therapies intended to cure viral infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for EBT-101, a CRISPR-based therapeutic candidate in development as a potential functional cure for chronic HIV.
-
Excision Announces NIH Martin Delaney Grant Awarded to Temple University to Support “CRISPR for Cure” for HIV
8/26/2021
Excision BioTherapeutics Inc announced that the Temple University team collaborating with Excision on a project, CRISPR for Cure, has received a Martin Delaney Grant from the National Institutes of Health of $4.8 million on an annual basis for the next five years as a part of approximately $53 million annual funding from the NIH to find a cure for HIV.
-
BioSpace Movers & Shakers, July 30, 2021
7/30/2021
Biopharma and life science companies strengthen their leadership teams and boards with these Movers & Shakers. -
Excision BioTherapeutics Appoints Industry Veteran Lisa Danzig, M.D., as Chief Medical Officer
7/29/2021
Excision BioTherapeutics Inc, the developer of CRISPR-based therapies intended to cure viral infectious diseases, today announced the appointment of Lisa Danzig, M.D., as Chief Medical Officer.
-
BioSpace Movers & Shakers, May 28
5/28/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Excision BioTherapeutics Appoints Infectious Disease Expert Sumathi Sivapalasingam, M.D, as Head of Translational Medicine
5/27/2021
Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the addition of infectious disease expert and clinical scientist Sumathi Sivapalasingam, M.D., as Head of Translational Medicine.
-
Excision BioTherapeutics Appoints Biotechnology Development and Manufacturing Veteran, Franz Gerner, Ph.D., as Chief Technology Officer & Head of Manufacturing
5/24/2021
Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the appointment of biotechnology industry development veteran, Franz Gerner, Ph.D., as Chief Technology Officer & Head of Manufacturing.